Societal CDMO (NASDAQ:SCTL – Get Rating) is one of 938 public companies in the “Pharmaceutical Preparations” sector, but how does it compare to its peers? We will compare Societal CDMO to similar companies based on the strength of its analyst recommendations, profitability, dividends, risk, valuation, institutional ownership and earnings.
Insider and Institutional Ownership
59.3% of Societal CDMO shares are held by institutional investors. Comparatively, 45.4% of the shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 7.8% of Societal CDMO shares are held by insiders of the company. In comparison, 14.9% of the shares of all “Pharmaceutical Preparations” companies are held by insiders of the company. Strong institutional ownership indicates that endowments, large fund managers, and hedge funds believe a stock will outperform the market over the long term.
Volatility and risk
Societal CDMO has a beta of 1.21, meaning its stock price is 21% more volatile than the S&P 500. Comparatively, Societal CDMO peers have a beta of 1.12, meaning its stock price average is 12% more volatile than the S&P 500.
This is a breakdown of the current recommendations for Societal CDMO and its peers, as provided by MarketBeat.com.
|Sales Ratings||Hold odds||Buy reviews||Strong buy odds||Rating|
|Societal CDMO||0||0||0||0||N / A|
|Societal competitors of CDMOs||6281||20841||43107||862||2.54|
As a group, the “Pharmaceutical preparations” companies have an upside potential of 132.71%. Since Societal CDMO peers have a higher likely upside potential, analysts clearly believe that Societal CDMO has less favorable growth aspects than its peers.
Valuation and benefits
This table compares the revenue, earnings per share (EPS), and valuation of Societal CDMO and its peers.
|Gross revenue||Net revenue||Price/earnings ratio|
|Societal CDMO||$75.36 million||-$11.37 million||-4.23|
|Societal competitors of CDMOs||$1.86 billion||$252.18 million||-2.22|
Societal CDMO peers have higher revenue and profit than Societal CDMO. Societal CDMO trades at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares the net margins, return on equity and return on assets of Societal CDMO and its peers.
|Net margins||Return on equity||return on assets|
|Societal competitors of CDMOs||-4,290.74%||-171.93%||-7.00%|
Societal CDMO peers beat societal CDMO on 5 of the 9 factors compared.
Societal profile of CDMO (Get a rating)
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the development, manufacturing and packaging of various therapeutic dosage forms primarily in small molecule therapeutic development in the United States and internationally . It offers its products as oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, eye droppers, liposomes and nano/microparticles, as well as in the fields of aseptic filling/finishing, freeze-drying, packaging and logistics services. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
Get news and reviews for Societal CDMO Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst notes for Societal CDMO and related companies with MarketBeat.com’s FREE daily newsletter.